Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a global leader
in laser- and light-based systems for aesthetic treatments, is
pleased to announce the launch of the Palomar Vectus™ Laser – the
intelligent choice for fast laser hair removal.
"Laser hair removal remains the most popular light-based
treatment offered1, with nearly one million treatments performed in
2011," said Joseph P. Caruso, President, Chief Executive Officer,
and Chairman of the Board. "The Palomar Vectus Laser offers
distinct advantages in speed, comfort, and confidence."
The Palomar Vectus Laser is a dedicated solution for high-volume
hair removal. It provides fast, uniform, permanent hair reduction
for the widest range of skin and hair types without sacrificing
comfort. The Palomar Vectus Laser features an integrated Skintel™
Melanin Reader, allowing providers to more safely offer laser hair
removal treatments with optimized outcomes tailored to each
client's skin type, sun exposure habits, and ethnicity.
Additionally, the Palomar Vectus Laser uses an intelligent user
interface, which allows the provider to quickly select treatment
parameters based on the client's hair density, hair color, hair
diameter, and Fitzpatrick Skin Type or Skintel Value.
"The Palomar Vectus Laser is absolutely superior to all other
existing technologies. Its large spot size allows us to treat male
backs or female legs within 20 minutes, and its parameters are
optimal for minimizing patient discomfort," said Josefina Royo de
la Torre, MD, an early user of the Palomar Vectus Laser at
Instituto Médico Laser in Madrid, Spain.
According to Nicola Otte, MD, of Dermatologikum Hamburg,
Hamburg, Germany, "Our patients are impressed by the Skintel
Melanin Reader and its ability to customize settings according to
their individual skin and hair color. Thanks to the good results
and the comfortable treatment, our patients prefer to be treated
with the Palomar Vectus Laser."
"No one knows more about light-based hair removal than Palomar,"
Mr. Caruso continued. "From receiving the first United States Food
and Drug Administration clearance for high-powered laser hair
removal in 1997, through this launch of the Palomar Vectus Laser,
Palomar has demonstrated a unique capability for continually
delivering advancements in this must-offer cosmetic
application."
To learn more about the Palomar Vectus Laser, please visit
www.palomarmedical.com/vectus.
1 The American Society for Aesthetic Plastic Surgery, 15th
Annual Cosmetic Surgery National Data Bank Statistics,
http://www.surgery.org/media/statistics
About Palomar Medical Technologies, Inc.:
Palomar is a leading researcher and developer of laser- and
light-based systems for aesthetic treatments.
Palomar pioneered the optical hair removal field, when, in 1997,
it introduced the first high-powered laser hair removal system.
Since then, many of the major advances in light-based hair removal
have been based on Palomar technology. As a pioneer of fractional
technology, Palomar is an owner of fundamental intellectual
property in this area. In June 2009, Palomar became the first
company to receive a 510(k) over-the-counter (OTC) clearance from
the FDA for a new, patented, home-use, fractional laser device for
the treatment of periorbital wrinkles. OTC clearance allows these
products to be marketed and sold directly to consumers without a
prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™
in December 2010. In December 2009, Palomar received the first FDA
clearance for the treatment of stretch marks using a fractional
non-ablative laser. In September 2010, Palomar received the first
FDA clearance for a fractional ablative and fractional non-ablative
combination treatment.
There are now millions of laser- and light-based aesthetic
procedures performed around the world every year in physician
offices, clinics, spas, salons, and homes. Palomar is testing many
new and exciting applications to further advance the aesthetic
market and other surgical applications.
For more information on Palomar and its products, visit
Palomar's website at palomarmedical.com.
With the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements, including, but not limited to, statements relating to
new markets, future royalty amounts due from third parties,
development and introduction of new products, and financial and
operating projections. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that
may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but
are not limited to, results of future operations, technological
difficulties in developing or introducing new products, the results
of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third
parties and government contracts, the impact of competitive
products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained
for future products and additional applications, the results of
litigation, difficulties in collecting royalties, potential
infringement of third-party intellectual property rights, factors
affecting the Company's future income and resulting ability to
utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on
Form 10-K for the year ended December 31, 2011 and the Company's
quarterly reports on Form 10-Q. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
release publicly the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
CONTACT: Press Contact:
Branden Morris
Integrated Marketing Manager
(781) 993-2452
bmorris@palomarmedical.com
Investor Relations Contact:
Kerry McAnistan
Investor Relations Assistant
(781) 993-2411
ir@palomarmedical.com
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From May 2023 to May 2024